Market Eyes LiveViking Therapeutics, Inc (VKTX) Stock Rating & Analysis
MELANY's data-driven read on Viking Therapeutics, Inc · Pharmaceutical Preparations.
Viking Therapeutics Inc is a biopharmaceutical company focused on metabolic and endocrine disorders. Its clinical pipeline includes VK2809 and VK0214, orally available tissue- and receptor-subtype-selective agonists of the thyroid hormone receptor beta, and VK5211, an orally available non-steroidal selective androgen receptor modulator.
Why VKTX scores 64/100
MELANY scores Viking Therapeutics, Inc 64/100 by weighing eight factors. Here is how VKTX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +19.3% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Analyst targets 138% upside
- Institutional net buying +10.0%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for VKTX
- Negative free cash flow, company consuming cash, not generating it
- Short interest 21% of float, high volatility risk on news
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Viking Therapeutics, Inc sits in the Healthcare sector theme, which MELANY currently rates 28/100 for strength. Theme strength feeds VKTX's momentum and catalyst factors above.
VKTX trade plan (members only)
MELANY has a full position plan for Viking Therapeutics, Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates VKTX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Viking Therapeutics, Inc's 64/100 reflects speculative factor weighting for its profile. Long-horizon position framework with quarterly score-based check-ins.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about VKTX
Is Viking Therapeutics, Inc (VKTX) a buy?
As of 2026-07-11, MELANY rates Viking Therapeutics, Inc Very Promising with a composite score of 64/100. This is an algorithmic, data-driven rating built from eight factors, not personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Viking Therapeutics, Inc's MELANY score?
Viking Therapeutics, Inc (VKTX) has a MELANY composite score of 64/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the VKTX stock rating calculated?
MELANY scores VKTX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
How current is this VKTX rating?
The rating on this page reflects MELANY's read as of 2026-07-11. The price shown updates live; the composite score refreshes continuously as new data arrives.
VKTX's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.